Psilocybin, often called magic mushrooms, is causing quite a stir in the scientific community with some fascinating new findings. A study from Emory University in Atlanta, Georgia, has revealed that this psychedelic compound might just extend the lifespan of cells and improve survival rates in older mice. This discovery is opening up discussions about psilocybin being a potential “potent geroprotective agent,” according to the researchers.
The research, which appeared in the journal Nature, is the first to show that psilocin, the active substance in psilocybin, could boost longevity in aged mice. Co-author Louise Hecker from Emory University shared that the data points to psilocybin impacting “multiple hallmarks of aging.” This includes reducing oxidative stress and preserving telomere length, which are DNA structures that help prevent cellular damage.
Interestingly, the mice treated with psilocybin seemed to age more gracefully, even regaining black hair that had turned white. Hecker explained in an interview with Fox News Digital that, “Psilocybin appears to slow the ‘wear and tear’ that accompanies aging.” This treatment had a significant impact on extending cellular life and improving the health and lifespan of the mice.
Despite the promising results, Hecker stressed that there’s still a lot to learn about psilocybin’s potential. Questions remain about the optimal dosing protocols for humans, the best age to start treatment, and any possible adverse effects over the long term. The study’s findings have sparked curiosity and excitement, but they also highlight the need for further research.
Gabe Charambides, the founder of Odyssey, America’s first legal psilocybin retreat in Oregon, finds these results “compelling.” While his retreat focuses on mental health benefits, such as relief from depression and anxiety, Charambides suggests that the physiological changes noted in the study might also apply to humans. Guests at his retreat have reported physical relief from issues like chronic pain and migraines.
Charambides emphasized the importance of administering psilocybin with care when it comes to humans, noting the differences in screening and preparation compared to mice. He mentioned that people who benefit most from psilocybin therapy often include those dealing with significant life changes or seeking to enhance their mental health.
Ryan Moss, chief science officer at Filament Health, a psychedelic drug development company, has highlighted the importance of a safe environment for psychedelic experiences. Moss warned that these experiences can sometimes involve anxiety, hallucinations, and paranoia, and that there have been reports of adverse cardiovascular events during clinical trials.
To ensure safety, Moss advises that participants in clinical trials undergo thorough preparation and monitoring by trained professionals. This approach aims to mitigate the potential risks associated with psychedelic treatments. The ongoing research into psilocybin continues to unfold, and the scientific and medical communities are keenly watching for more insights into its effects and potential applications.
